Novartis

Novartis is in the middle of its toughest transformation phase since the Alcon spin-off in 2019. The biggest cash cow Entresto (heart failure, $7.8B revenue 2025) loses US patent protection mid-2026 — generics could take 60-75% of the market by early 2027. At the same time Cosentyx faces rising biosimilar and new IL-17/IL-23 antibody competition. In total, about 25% of Novartis revenue is at stake over the next 30 months.

The real 2026 investment setup, however, is the Pluvicto story: Novartis built the market-leading radioligand therapy platform with the Endocyte acquisition (2018) and Advanced Accelerator Applications (2017). Pluvicto currently treats metastatic prostate cancer in the late line ($1.9B revenue 2025) — FDA approval for the first-line indication is expected Q3 2026. Addressable patient population quadruples to ~80,000 US patients annually, which could lever Pluvicto to $8-12B revenue by 2030.

Three other pipeline levers: Iptacopan (PNH, paroxysmal nocturnal hemoglobinuria — anemia indication Q2 2026 expected), Kisqali (breast cancer adjuvant setting fully launched), Leqvio (PCSK9 inhibitor cholesterol — 2026 real-world data should show better than statins).

Novartis is classically held by European pharma specialists, less by US smart-money stars. Capital Group holds 87M shares (3.3% outstanding), BlackRock 4.9%, Vanguard 3.2% — all ETF-driven, hardly conviction bets. Classic stock pickers like Wellington reduced their NOVN position by 1.5% in Q4/2025, apparently due to Entresto cliff concerns.

Notable: Renaissance Technologies opened a long position in NOVN in Q1/2026 for the first time since 2022 — 1.2M ADRs (worth ~$140M) — possibly triggered by the Pluvicto Q3 approval setup as a pair trade against Eli Lilly or Pfizer.

Insider: CEO Vasant Narasimhan has not sold any shares since November 2024, which is unusual in the Swiss pharma world (the standard quarterly 10b5 sale program is absent). Interpretation: management believes in the pipeline story and does not want to send bearish signals.

Novartis trades at a forward P/E of 15.5 and EV/EBITDA of 13.2 — both below the 10-year median (P/E 17, EV/EBITDA 14.5). But: the fundamental question is not whether the valuation is cheap, but whether the market correctly prices the Entresto cliff. Three models: (1) Sum-of-drugs model: at consensus 2027 pipeline revenue (Pluvicto $4B, Kisqali $5B, Iptacopan $2B, Leqvio $2B, Cosentyx $5B, Entresto residual $1B, plus remaining portfolio $32B), group revenue works out to $51B vs consensus $48B. At 30% net margin: EPS $7.20 vs consensus $6.80. (2) Mean reversion: at P/E 17 and $7.20 EPS 2027 = CHF 145 vs current CHF 117. (3) Worst case: with delayed Pluvicto approval and accelerated Entresto cliff, EPS $5.80 → at P/E 14 = CHF 95 (downside -18%). Asymmetry is favorable but not extreme.

1. Q3 2026: FDA PDUFA Pluvicto first-line metastatic prostate cancer — biggest pipeline driver of the next 24 months
2. July 2026: Q2 2026 earnings with Entresto generic launch update — first quarter with visible cliff impact
3. September 2026: ESMO congress in Berlin — Kisqali NATALEE update plus Pluvicto PSMAfore data, often stock-moving

Novartis in 2026 is a double-edged sword: on one side one of the most exciting pharma pipelines globally (Pluvicto, Iptacopan, Leqvio), on the other side the hardest patent cliff since Pfizer-Lipitor. My take: the risk-reward is asymmetrically positive, but the next 12 months will be volatile. 24-month price target: CHF 135-145 if Pluvicto approval and good Q3 data arrive. Stop-loss level: CHF 95 (worst-case EPS model). For international investors: 35% Swiss withholding tax (15% creditable via tax treaty, remaining 20% not recoverable for most). At 3.2% gross yield, net is only 2.1-2.5% — not particularly attractive as a pure income choice. Position in my portfolio: 2% as a pipeline speculation, not a core holding. If you want pharma but want to avoid the cliff risk: Lilly or Roche are the cleaner options.